DOI
10.3389/fphar.2026.1781517
Abstract
Children with epilepsy frequently experience a range of significant comorbidities beyond seizures, such as motor dysfunction, cognitive impairment, and neurodevelopmental delays. In some cases, these comorbidities contribute more significantly to overall disease burden than the seizures themselves. To improve quality-of-life (QOL) for these children, treatment options should be selected that control seizures and ameliorate comorbidities. Unfortunately, such therapeutics remain largely elusive. Addressing this issue requires suitable preclinical models. Here we used CRISPR-generated zebrafish with single-gene mutations linked to pediatric epilepsy and applied clinically-relevant behavioral assays to study the effects of these mutations. Using high-throughput locomotion-based assays, we uncovered errors in sensorimotor integration in larval scn1lab, stxbp1b, arxa and gabrb3 zebrafish mutants at 6 days post-fertilization (dpf) compared to wild-type sibling controls. Strikingly abnormal exploratory and preference responses were also observed in scn1lab and stxbp1b zebrafish mutants. Pharmacological testing revealed that, compared to stiripentol and valproic acid, clemizole produced the most extensive rescue of deficits in scn1lab mutants. Within the broader epilepsy research landscape, this study further supports the use of zebrafish as a robust, dual platform to understand and discover novel therapeutics for epilepsy and its associated behavioral comorbidities.
Document Type
Article
Publication Date
5-3-2026
Publisher Statement
COPYRIGHT © 2026 Ononuju, Hall, Beatty, Baraban and Carpenter-Swanson. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Recommended Citation
Ononuju C, Hall K, Beatty O, Baraban SC and Carpenter-Swanson C (2026) Employing zebrafish to understand genetic drivers of epilepsy-related comorbid behaviors. Front. Pharmacol. 17:1781517. doi: 10.3389/fphar.2026.1781517
